Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Cardiology

Evaluating Your Risk and Diagnosis

At a Glance

Doctors estimate atherosclerosis-related heart attack and stroke risk using 10-year calculators, medical history, cholesterol and blood pressure results, and targeted tests such as CAC and ABI. These findings help guide lifestyle and statin decisions.

Determining your risk for heart attack or stroke is not a matter of guesswork. Doctors use validated mathematical tools and specific diagnostic tests to categorize your risk and decide how aggressively to manage factors like cholesterol and blood pressure [1][2]. The pathway used depends heavily on whether you are seeking primary prevention (you do not have known disease) or secondary prevention (you already have clinical atherosclerosis).

Calculating Your Risk Score (Primary Prevention)

For people who do not yet have known clinical heart disease, the first step is calculating a 10-year risk score. This estimate predicts the likelihood that you will experience a major cardiovascular event in the next decade [1].

The Pooled Cohort Equations (US)

In the United States, the standard tool is the ASCVD Pooled Cohort Equations (PCE). It is designed for adults aged 40–75 and uses your age, sex, race, cholesterol levels, blood pressure, and smoking status to place you into one of four categories [1][3]:

  • Low Risk (<5%): Focus is on maintaining a healthy lifestyle. Preventive medication is usually not needed [1].
  • Borderline Risk (5% to <7.5%): If you have “risk-enhancing factors” (like a family history of early heart disease), a statin might be considered [3].
  • Intermediate Risk (7.5% to <20%): A detailed discussion with your doctor is recommended to weigh the benefits of starting a statin [3][1].
  • High Risk (≥20%): Preventive medication is strongly advised because the risk of an event is significantly elevated [1].

SCORE2 and SCORE2-OP (Europe)

In Europe, doctors use SCORE2 (for ages 40–69) and SCORE2-OP (for ages 70+). These tools are tailored to specific regions of Europe, as heart disease rates vary significantly by country [2][4]. Like the US tool, these help categorize patients to determine when lifestyle changes alone are enough or if medication is necessary [5][6].

Important Exceptions: These calculators are not meant to decide treatment if you already have clinical ASCVD, LDL-C of at least 190 mg/dL, or if you are an adult with diabetes; in those situations, treatment is usually indicated independently of the calculated score.

Refining the Results

Sometimes, a primary prevention risk score is not enough to make a clear decision. In these cases, “risk-refinement” tests can provide more detail.

Coronary Artery Calcium (CAC) Score

A CAC score is a specialized CT scan that looks for “hard” or calcified plaque in the arteries of the heart [7].

  • When it’s used: It is most helpful for people in the borderline or intermediate categories who are unsure about starting a statin [7][8]. It is not a universal screening tool for everyone [9].
  • Understanding a 0 score: A score of 0 is very reassuring and often means a statin can be delayed, provided you don’t have high-risk factors like heavy smoking, diabetes, or a very strong family history [7][10]. However, a 0 does not completely rule out risk, especially in younger people who may have “soft” (non-calcified) plaque, so a reassessment interval is usually needed [11][12].

Ankle-Brachial Index (ABI)

The ABI is a simple test that compares the blood pressure at your ankle to the blood pressure in your arm [13].

  • Diagnosis: An ABI score below 0.9 is a primary way to diagnose Peripheral Artery Disease (PAD) [13].
  • Risk Enhancement: Even if you don’t have leg symptoms, a low ABI is considered a “risk-enhancing factor” that may move you into a higher risk category, suggesting that more intensive prevention is needed [13][9].

Looking Beyond LDL

While LDL-C (“bad” cholesterol) is the main target for treatment, other markers help identify residual risk—the risk that remains even after LDL is lowered [14][15]:

  • Non-HDL Cholesterol: Calculated as Total Cholesterol minus HDL (“good” cholesterol), this captures all potentially harmful cholesterol particles and is a powerful predictor of risk [15][16].
  • Lipoprotein(a) [Lp(a)]: This is a largely genetically determined lipoprotein particle. Elevated levels are an independent risk factor for heart disease and stroke, and testing it generally prompts more intensive management of modifiable risk factors [17][15].
  • Triglycerides: High levels of these fats in the blood can indicate persistent risk, even if your LDL is well-controlled [18][19].

Your doctor will use these tools together—the calculated score, your unique risk factors, and any refining tests—to build a prevention plan that fits your specific profile [6][14].

Common questions in this guide

How do doctors calculate my 10-year heart attack and stroke risk?
In the United States, the ASCVD Pooled Cohort Equations estimate risk for many adults ages 40 to 75 using age, sex, race, cholesterol levels, blood pressure, and smoking status. The result places you in a low, borderline, intermediate, or high-risk group and helps guide prevention discussions. European clinicians may use SCORE2 or SCORE2-OP, which are adjusted for regional differences.
What do the different 10-year risk categories mean?
Under 5% is low risk, 5% to under 7.5% is borderline, 7.5% to under 20% is intermediate, and 20% or higher is high risk in the US categories. Lower categories usually emphasize lifestyle, while borderline or intermediate results may prompt discussion of risk-enhancing factors, a CAC test, or a statin. A high result generally supports preventive medication, but your clinician interprets it with your full history.
When can a coronary artery calcium score help with a statin decision?
A CAC score comes from a specialized CT scan that detects calcified plaque in the heart arteries. It is most useful when someone has borderline or intermediate risk and is unsure about starting a statin, rather than as a screening test for everyone. A score of zero is reassuring but does not eliminate risk, especially with diabetes, heavy smoking, a strong family history, or younger age.
What does an ankle-brachial index test show?
An ABI compares blood pressure at the ankle with blood pressure in the arm. A result below 0.9 supports a diagnosis of peripheral artery disease, even if you have no leg symptoms, and can act as a risk-enhancing finding. Your clinician uses it with other information to decide how intensively to manage cardiovascular risk.
What do non-HDL cholesterol, Lipoprotein(a), and triglycerides add to my risk assessment?
Non-HDL cholesterol is total cholesterol minus HDL cholesterol and reflects several potentially harmful cholesterol particles. Lipoprotein(a) is largely inherited, and a high level independently increases heart and stroke risk; high triglycerides can also signal residual risk even when LDL cholesterol is controlled. These results may lead to more intensive management of changeable risk factors.
Do standard risk calculators apply if I have diabetes, very high LDL, or known ASCVD?
Standard risk calculators are not intended to determine treatment when you already have clinical atherosclerotic cardiovascular disease, an LDL cholesterol level of at least 190 mg/dL, or diabetes as an adult. In these situations, treatment is generally recommended based on the condition itself rather than the calculated percentage. Your clinician can still use your history and test results to tailor the plan.
How should I decide about a statin if my risk is intermediate?
If your risk is intermediate, ask your clinician about the expected benefit of a statin, possible adverse effects, and whether a CAC scan or risk-enhancing factors could clarify the decision. The choice should consider your cholesterol, blood pressure, family history, other test results, and preferences. Reassessment may be reasonable when the decision is uncertain.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my blood pressure, cholesterol, and other factors, what is my estimated 10-year risk score?
  2. 2.Do I have any 'risk-enhancing factors,' like a family history of early heart disease, that aren't captured by the standard calculator?
  3. 3.Would a Coronary Artery Calcium (CAC) score help clarify whether I need a statin, or is my risk already clear enough to decide?
  4. 4.Since you're checking my cholesterol, will we also be looking at my non-HDL-C or Lipoprotein(a) to get a fuller picture of my risk?
  5. 5.If we find that my risk is intermediate, what are the pros and cons of starting a statin now versus waiting and re-evaluating later?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Assessment of Atherosclerotic Cardiovascular Disease Risk in Primary Prevention.

    Rikhi R, Shapiro MD

    Journal of cardiopulmonary rehabilitation and prevention 2022; (42(6)):397-403 doi:10.1097/HCR.0000000000000746.

    PMID: 36342682
  2. 2

    New Way to "SCORE" Risk: Updates on the ESC Scoring System and Incorporation into ESC Cardiovascular Prevention Guidelines.

    Graham IM, Di Angelantonio E, Huculeci R,

    Current cardiology reports 2022; (24(11)):1679-1684 doi:10.1007/s11886-022-01790-6.

    PMID: 36441402
  3. 3

    2018 Cholesterol Clinical Practice Guidelines: Synopsis of the 2018 American Heart Association/American College of Cardiology/Multisociety Cholesterol Guideline.

    Grundy SM, Stone NJ,

    Annals of internal medicine 2019; (170(11)):779-783 doi:10.7326/M19-0365.

    PMID: 31132793
  4. 4

    SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions.

    European heart journal 2021; (42(25)):2455-2467 doi:10.1093/eurheartj/ehab312.

    PMID: 34120185
  5. 5

    Statin Eligibility for Primary Prevention of Cardiovascular Disease According to 2021 European Prevention Guidelines Compared With Other International Guidelines.

    Mortensen MB, Tybjærg-Hansen A, Nordestgaard BG

    JAMA cardiology 2022; (7(8)):836-843 doi:10.1001/jamacardio.2022.1876.

    PMID: 35793078
  6. 6

    Statement of the Spanish Interdisciplinary Vascular Prevention Committee on the updated European Guidelines on Cardiovascular Disease Prevention.

    Brotons C, Camafort M, Castellanos MDM, et al.

    Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis 2022; (34(4)):219-228 doi:10.1016/j.arteri.2022.03.003.

    PMID: 35906022
  7. 7

    The Evolving View of Coronary Artery Calcium: A Personalized Shared Decision-Making Tool in Primary Prevention.

    Dzaye O, Reiter-Brennan C, Osei AD, et al.

    Cardiology research and practice 2019; (2019()):7059806 doi:10.1155/2019/7059806.

    PMID: 31511792
  8. 8

    Role of Coronary Artery Calcium Testing for Risk Assessment in Primary Prevention of Atherosclerotic Cardiovascular Disease: A Review.

    Greenland P, Lloyd-Jones DM

    JAMA cardiology 2022; (7(2)):219-224 doi:10.1001/jamacardio.2021.3948.

    PMID: 34613362
  9. 9

    Subclinical Hypertension-Mediated Organ Damage (HMOD) in Hypertension: Atherosclerotic Cardiovascular Disease (ASCVD) and Calcium Score.

    Rizzoni D, Agabiti-Rosei C, De Ciuceis C, Boari GEM

    High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension 2023; (30(1)):17-27 doi:10.1007/s40292-022-00551-4.

    PMID: 36376777
  10. 10

    Implications of Coronary Artery Calcium Testing Among Statin Candidates According to American College of Cardiology/American Heart Association Cholesterol Management Guidelines: MESA (Multi-Ethnic Study of Atherosclerosis).

    Nasir K, Bittencourt MS, Blaha MJ, et al.

    Journal of the American College of Cardiology 2015; (66(15)):1657-68.

    PMID: 26449135
  11. 11

    Age and the power of zero CAC in cardiac risk assessment: overview of the literature and a cautionary case.

    Sheppard JP, Lakshmanan S, Lichtenstein SJ, et al.

    The British journal of cardiology 2022; (29(3)):23 doi:10.5837/bjc.2022.023.

    PMID: 36873724
  12. 12

    Assessment of Coronary Artery Calcium Scoring to Guide Statin Therapy Allocation According to Risk-Enhancing Factors: The Multi-Ethnic Study of Atherosclerosis.

    Patel J, Pallazola VA, Dudum R, et al.

    JAMA cardiology 2021; (6(10)):1161-1170 doi:10.1001/jamacardio.2021.2321.

    PMID: 34259820
  13. 13

    Utility of Nontraditional Risk Markers in Individuals Ineligible for Statin Therapy According to the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines.

    Yeboah J, Polonsky TS, Young R, et al.

    Circulation 2015; (132(10)):916-22 doi:10.1161/CIRCULATIONAHA.115.016846.

    PMID: 26224808
  14. 14

    The importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: Lower for longer is better.

    Mhaimeed O, Burney ZA, Schott SL, et al.

    American journal of preventive cardiology 2024; (18()):100649 doi:10.1016/j.ajpc.2024.100649.

    PMID: 38576462
  15. 15

    Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM.

    Nordestgaard BG, Langlois MR, Langsted A, et al.

    Atherosclerosis 2020; (294()):46-61 doi:10.1016/j.atherosclerosis.2019.12.005.

    PMID: 31928713
  16. 16

    Lipid measurements in the management of cardiovascular diseases: Practical recommendations a scientific statement from the national lipid association writing group.

    Wilson PWF, Jacobson TA, Martin SS, et al.

    Journal of clinical lipidology 2021; (15(5)):629-648 doi:10.1016/j.jacl.2021.09.046.

    PMID: 34802986
  17. 17

    Independence of Lipoprotein(a) and Low-Density Lipoprotein Cholesterol-Mediated Cardiovascular Risk: A Participant-Level Meta-Analysis.

    Bhatia HS, Wandel S, Willeit P, et al.

    Circulation 2025; (151(4)):312-321 doi:10.1161/CIRCULATIONAHA.124.069556.

    PMID: 39492722
  18. 18

    Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics.

    Boden WE, Bhatt DL, Toth PP, et al.

    European heart journal 2020; (41(24)):2304-2312 doi:10.1093/eurheartj/ehz778.

    PMID: 31872245
  19. 19

    Elevated triglycerides are related to higher residual cardiovascular disease and mortality risk independent of lipid targets and intensity of lipid-lowering therapy in patients with established cardiovascular disease.

    Schuitema PCE, Visseren FLJ, Nordestgaard BG, et al.

    Atherosclerosis 2025; (408()):120411 doi:10.1016/j.atherosclerosis.2025.120411.

    PMID: 40579281

This page is for informational purposes only and does not constitute medical advice. Ask your healthcare professional to interpret your atherosclerosis risk score and test results and discuss treatment choices.

Get notified when new evidence is published on atherosclerosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.